Antiemetic Prophylaxis with Fosaprepitant and 5-HT₃-Receptor Antagonists in Pediatric Patients Undergoing Autologous Hematopoietic Stem Cell Transplantation

References

• BarrettD, FishJD, GruppSA. Autologous and allogeneic cellular therapies for high-risk pediatric solid tumors. Pediatr Clin North Am. 2010;57(1):47–66. doi:10.1016/j.pcl.2010.01.00120307711
   PubMed Web of Science ®Google Scholar
• HaleGA. Autologous hematopoietic stem cell transplantation for pediatric solid tumors. Expert Rev Anticancer Ther. 2005;5(5):835–846. doi:10.1586/14737140.5.5.83516221053
   PubMed Web of Science ®Google Scholar
• PeinemannF, EnkH, SmithLA. Autologous hematopoietic stem cell transplantation following high-dose chemotherapy for nonrhabdomyosarcoma soft tissue sarcomas. Cochrane Database Syst Rev. 2017;4:Cd008216.28407197
   PubMed Web of Science ®Google Scholar
• YalcinB, KremerLC, van DalenEC. High-dose chemotherapy and autologous haematopoietic stem cell rescue for children with high-risk neuroblastoma. Cochrane Database Syst Rev. 2015;10:Cd006301.
   Google Scholar
• GardnerSL. Application of stem cell transplant for brain tumors. Pediatr Transplant. 2004;8(Suppl 5):28–32. doi:10.1111/j.1398-2265.2004.00202.x15125703
   PubMed Web of Science ®Google Scholar
• SchreyD, Carceller LechonF, MalietzisG, et al. Multimodal therapy in children and adolescents with newly diagnosed atypical teratoid rhabdoid tumor: individual pooled data analysis and review of the literature. J Neurooncol. 2016;126(1):81–90. doi:10.1007/s11060-015-1904-026608522
   PubMed Web of Science ®Google Scholar
• de JongMC, KorsWA, de GraafP, CastelijnsJA, KivelaT, MollAC. Trilateral retinoblastoma: a systematic review and meta-analysis. Lancet Oncol. 2014;15(10):1157–1167. doi:10.1016/S1470-2045(14)70336-525126964
   PubMed Web of Science ®Google Scholar
• BurdachS, van KaickB, LawsHJ, et al. Allogeneic and autologous stem-cell transplantation in advanced Ewing tumors. An update after long-term follow-up from two centers of the European Intergroup study EICESS. Stem-Cell Transplant Programs at Dusseldorf University Medical Center, Germany and St. Anna Kinderspital, Vienna, Austria. Ann Oncol. 2000;11(11):1451–1462. doi:10.1023/a:102653990811511142486
   PubMed Web of Science ®Google Scholar
• Pädiatrische Arbeitsgemeinschaft für Stammzelltransplantation und Zelltherapie (PAS&ZT) Deutschland. Kooperatives Pädiatrisches Register für Stammzell Transplantationen der Pädiatrischen Arbeitsgemeinschaft - Bericht 2017/2018; 2019 [updated April 2, 2019] Available from:http://www.drst.de/drst/download/prst_jb2017_2018.pdf. Accessed 425, 2020.
   Google Scholar
• FlankJ, SparavaloJ, VolH, et al. The burden of chemotherapy-induced nausea and vomiting in children receiving hematopoietic stem cell transplantation conditioning: a prospective study. Bone Marrow Transplant. 2017;52(9):1294–1299. doi:10.1038/bmt.2017.11228581463
   PubMed Web of Science ®Google Scholar
• KusnierczykNM, SaundersEF, DupuisLL. Outcomes of antiemetic prophylaxis in children undergoing bone marrow transplantation. Bone Marrow Transplant. 2002;30(2):119–124. doi:10.1038/sj.bmt.170357912132051
   PubMed Web of Science ®Google Scholar
• European Medicines Agency (EMA) - Committee for Medicinal Products for Human Use (CHMP). Assessment report Ivemend - Procedure No. EMEA/H/C/000743/II/0037; 2018 Available from:https://www.ema.europa.eu/documents/variation-report/ivemend-h-c-743-ii-0037-epar-assessment-report-variation_en.pdf. Accessed 1212, 2018.
   Google Scholar
• US Food and Drug Administration. EMEND - Fosaprepitant Dimeglumine. NDA 022023 - SUPPL-17. SUPPL-17 Web site; 2018 Available from:https://www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/DevelopmentResources/UCM605696.pdf. Accessed 1212, 2018.
   Google Scholar
• DupuisLL, SungL, MolassiotisA, OrseyAD, TissingW, van de WeteringM. 2016 updated MASCC/ESMO consensus recommendations: prevention of acute chemotherapy-induced nausea and vomiting in children. Support Care Cancer. 2017;25(1):323–331. doi:10.1007/s00520-016-3384-y27565788
   PubMed Web of Science ®Google Scholar
• PatelP, RobinsonPD, ThackrayJ, et al. Guideline for the prevention of acute chemotherapy-induced nausea and vomiting in pediatric cancer patients: A focused update. Pediatr Blood Cancer. 2017;64(10):e26542. doi:10.1002/pbc.26542
   Web of Science ®Google Scholar
• AaproM, CaridesA, RapoportBL, SchmollHJ, ZhangL, WarrD. Aprepitant and fosaprepitant: a 10-year review of efficacy and safety. Oncologist. 2015;20(4):450–458. doi:10.1634/theoncologist.2014-022925795636
   PubMed Web of Science ®Google Scholar
• Cabanillas StanchiKM, EbingerM, HartmannU, et al. Efficacy, safety and feasibility of antiemetic prophylaxis with fosaprepitant, granisetron and dexamethasone in pediatric patients with hemato-oncological malignancies. Drug Des Devel Ther. 2019;13:3439–3451. doi:10.2147/DDDT.S214264
   PubMed Web of Science ®Google Scholar
• Cabanillas StanchiKM, VekJ, SchlegelP, et al. Antiemetic prophylaxis with fosaprepitant and granisetron in pediatric patients undergoing allogeneic hematopoietic stem cell transplantation. J Cancer Res Clin Oncol. 2020;146(4):1089–1100. doi:10.1007/s00432-020-03143-832056007
   PubMed Web of Science ®Google Scholar
• CelioL, RicchiniF, De BraudF. Safety, efficacy, and patient acceptability of single-dose fosaprepitant regimen for the prevention of chemotherapy-induced nausea and vomiting. Patient Prefer Adherence. 2013;7:391–400. doi:10.2147/PPA.S3128823687442
   PubMed Web of Science ®Google Scholar
• ClarkSM, ClemmonsAB, SchaackL, GarrenJ, DeRemerDL, KotaVK. Fosaprepitant for the prevention of nausea and vomiting in patients receiving BEAM or high-dose melphalan before autologous hematopoietic stem cell transplant. J Oncol Pharm Pract. 2016;22(3):416–422. doi:10.1177/107815521558519025956421
   PubMed Web of Science ®Google Scholar
• ClemmonsAB, OrrJ, AndrickB, GandhiA, SportesC, DeRemerD. Randomized, Placebo-Controlled, Phase III Trial of Fosaprepitant, Ondansetron, Dexamethasone (FOND) Versus FOND Plus Olanzapine (FOND-O) for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Patients with Hematologic Malignancies Receiving Highly Emetogenic Chemotherapy and Hematopoietic Cell Transplantation Regimens: the FOND-O Trial. Biol Blood Marrow Transplant. 2018;24(10):2065–2071. doi:10.1016/j.bbmt.2018.06.00529906570
   PubMed Web of Science ®Google Scholar
• DuquetteD, AdamJP, GouletD, DelageR. Retrospective analysis of the efficacy of antiemetic prophylaxis in different preparative regimens for autologous and allogeneic bone marrow transplantation. Biol Blood Marrow Transplant. 2011;17(2):S282. doi:10.1016/j.bbmt.2010.12.389
   Web of Science ®Google Scholar
• WillierS, Cabanillas StanchiKM, von HaveM, et al. Efficacy, safety and feasibility of fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting in pediatric patients receiving moderately and highly emetogenic chemotherapy - results of a non-interventional observation study. BMC Cancer. 2019;19(1):1118. doi:10.1186/s12885-019-6252-631730451
   PubMed Web of Science ®Google Scholar
• DupuisLL, BoodhanS, SungL, et al. Guideline for the classification of the acute emetogenic potential of antineoplastic medication in pediatric cancer patients. Pediatr Blood Cancer. 2011;57(2):191–198. doi:10.1002/pbc.2311421465637
   PubMed Web of Science ®Google Scholar
• U.S. NIH -NCI. Common terminology criteria for adverse events v4.03 (CTCAE) 2010. May 28, 2009; 2010.
   Google Scholar
• PatelP, LeederJS, Piquette-MillerM, DupuisLL. Aprepitant and fosaprepitant drug interactions: a systematic review. Br J Clin Pharmacol. 2017;83(10):2148–2162. doi:10.1111/bcp.1332228470980
   PubMed Web of Science ®Google Scholar
• TrifilioS, WellesC, SeegerK, et al. Olanzapine reduces chemotherapy-induced nausea and vomiting compared with aprepitant in myeloma patients receiving high-dose melphalan before stem cell transplantation: a retrospective study. Clin Lymphoma Myeloma Leuk. 2017;17(9):584–589. doi:10.1016/j.clml.2017.06.01228694084
   PubMed Web of Science ®Google Scholar
• RadhakrishnanV, JoshiA, RamamoorthyJ, et al. Intravenous fosaprepitant for the prevention of chemotherapy-induced vomiting in children: A double-blind, placebo-controlled, phase III randomized trial. Pediatr Blood Cancer. 2018;e27551.30426714
   PubMed Web of Science ®Google Scholar
• SaitoY, KumamotoT, ArimaT, et al. Evaluation of aprepitant and fosaprepitant in pediatric patients. Pediatr Int. 2019;61(3):235–239. doi:10.1111/ped.1378030615239
   PubMed Web of Science ®Google Scholar
• ShillingburgA, BiondoL. Aprepitant and fosaprepitant use in children and adolescents at an academic medical center. J Pediatr Pharmacol Ther. 2014;19(2):127–131. doi:10.5863/1551-6776-19.2.12725024673
   PubMedGoogle Scholar
• TimaeusS, ElderJ, FrancoK. Evaluation of the use of fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting in pediatric patients. J Pediatr Hematol Oncol. 2018;40(7):527–531. doi:10.1097/MPH.000000000000121329794645
   PubMed Web of Science ®Google Scholar
• OrchardPJ, RogosheskeJ, BurnsL, et al. A prospective randomized trial of the anti-emetic efficacy of ondansetron and granisetron during bone marrow transplantation. Biol Blood Marrow Transplant. 1999;5(6):386–393. doi:10.1016/S1083-8791(99)70015-710595816
   PubMedGoogle Scholar
• WalshT, MorrisAK, HolleLM, et al. Granisetron vs ondansetron for prevention of nausea and vomiting in hematopoietic stem cell transplant patients: results of a prospective, double-blind, randomized trial. Bone Marrow Transplant. 2004;34(11):963–968. doi:10.1038/sj.bmt.170471415489869
   PubMed Web of Science ®Google Scholar
• Fox-GeimanMP, FisherSG, KileyK, Fletcher-GonzalezD, PorterN, StiffP. Double-blind comparative trial of oral ondansetron versus oral granisetron versus IV ondansetron in the prevention of nausea and vomiting associated with highly emetogenic preparative regimens prior to stem cell transplantation. Biol Blood Marrow Transplant. 2001;7(11):596–603. doi:10.1053/bbmt.2001.v7.pm1176014711760147
   PubMed Web of Science ®Google Scholar
• DupuisLL, TaddioA, KerrEN, KellyA, MacKeiganL. Development and validation of the pediatric nausea assessment tool for use in children receiving antineoplastic agents. Pharmacotherapy. 2006;26(9):1221–1231. doi:10.1592/phco.26.9.122116945043
   PubMed Web of Science ®Google Scholar